"Human embryonic stem cells promise unrivalled opportunities. However, they are difficult, time-consuming and expensive to grow in the lab", says Dr. Chris Denning of Institute of Genetics, who is working on research looking at the process that turns a stem cell into a cardiomyocyte - the beating cell that makes up the heart.
The Nottingham researchers are developing a new system to monitor cardiomyocytes in real time as they differentiate from stem cells into beating heart cells. The system uses electrophysiology to record the electrical properties in a cell. The researchers hope that their research could provide more detailed information on the electrical activity of stem cell derived cardiomyocytes.
"Our understanding of how to convert them into cardiomyocytes is poor. At the moment we only know how to produce a few million cardiomyocytes, but to treat just one heart attack patient, we may need one billion that all function in the correct way," says Denning.
To help overcome the many challenges that stem cells bring, Dr Denning and his team plan to engineer a novel system for real-time analysis of cardiomyocytes during early development so their properties are better understood. The team have already demonstrated that sufficient numbers of stem cell-derived cardiomyocytes can be produced for detailed analysis.
In the longer term, this could facilitate their use in regenerating the damaged hearts of heart attack victims.
"Before we can consider using stem cells to treat heart-attack patients there are many problems which will take many years to solve," he says, "We don't yet know how to deliver the cells to a patient's heart and prevent them being washed away so that they actually stay in the heart and both survive and function. It will take many years to overcome these challenges and put stem cell-derived cardiomyocytes into medical usage.
"Between 1990 and 2001, 8 different drugs were withdrawn from the market in the USA at an estimated cost of $8billion because they caused unexpected deaths in several hundred patients. Our aim is to reduce such occurrences by having better test methods to test the drugs before they reach the clinic.
"By studying the drugs' effects on the heart cells in the lab, this could reduce the need for animals in clinical trials."
Funding: Biotechnology and Biological Sciences Research Council